Articles
Canada’s patchwork of ‘orphan’ drug policies

Canada’s patchwork of ‘orphan’ drug policies

Ravi Singh explores the unique challenges drug manufacturers face in Canada with their current orphan drug policies and shares his thoughts on what the future looks like. Manufacturers of drugs that treat orphan diseases face unique challenges in Canada. Unlike other countries with orphan drug policies that...

Articles
A guide for international pharmaceutical communications: What do we really mean by brand value? (Part 1)

A guide for international pharmaceutical communications: Wha...

Sunil Ramkali presents some key insights on how to deliver a brand that truly addresses market needs in the pharmaceutical industry. Is developing differentiated brand communications that deliver real world value and drive brand uptake your goal? If so, understanding...

Articles
A new foundation for designing winning brand strategies - the Patient Journey re-envisioned

A new foundation for designing winning brand strategies - th...

Maneesh Gupta talks us through the importance of understanding the Patient Journey in creating a successful brand strategy. Medicine has been described as a “science of uncertainty and an art of probability”. The same can be said of marketing, particularly when it comes to...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more